Sleepy Eye Medical Center Critical Access Hospital (Medicare Certified) Location: 400 Fourth Avenue Northwest, Sleepy Eye, Minnesota 56085 Ratings:NA Phone: (507) 794-3571 |
News Archive
Raptor Pharmaceutical Corp., announced positive findings from the completed treatment phase of its open-label Phase 2a clinical trial of delayed-release cysteamine bitartrate ("DR Cysteamine") in adolescent patients with non-alcoholic steatohepatitis ("NASH"), a progressive form of liver disease believed to affect 2% to 5% of the U.S. population.
Sudden cardiac arrest is a possible cause of death in patients with non-ischaemic cardiac muscle weakness, i.e. a type of heart failure caused by genetics or for which no cause is known. Now, researchers at the University Department of Internal Medicine II at the MedUni Vienna (Clinical Department of Cardiology), as part of an international cooperation, have successfully demonstrated the advantages of an implanted defibrillator (ICD) as a means of prevention in patients with moderately restricted cardiac function, and that patients with the condition must be treated as carefully as patients with ischaemic heart failure which has developed following a heart attack, for example.
Harvest Technologies Corp. announced today that the company sponsored 48-patient IDE clinical trial conducted at seven sites in the U.S. and one site in India using the company's Bone Marrow Aspiration Concentrate (BMAC) System to treat patients with non-reconstructable Critical Limb Ischemia (CLI) has completed enrollment. Mark D. Iafrati, M.D. Chief of Vascular Surgery at Tufts Medical Center in Boston, directed the study.
It's already for the fourth time, that Prof. Dr. K. Lenhard Rudolph, scientific director of the Leibniz Institute for Age Research - Fritz Lipmann Institute (FLI) calls the scientific elite of international stem cell researchers to join at Else Kröner Fresenius (EKF) Symposium on Adult Stem Cells in Aging, Diseases and Cancer.
› Verified 1 days ago